SE501678C2 - Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid - Google Patents

Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid

Info

Publication number
SE501678C2
SE501678C2 SE9302414A SE9302414A SE501678C2 SE 501678 C2 SE501678 C2 SE 501678C2 SE 9302414 A SE9302414 A SE 9302414A SE 9302414 A SE9302414 A SE 9302414A SE 501678 C2 SE501678 C2 SE 501678C2
Authority
SE
Sweden
Prior art keywords
peptide
pharmaceutical composition
administration
alpha
ile
Prior art date
Application number
SE9302414A
Other languages
English (en)
Swedish (sv)
Other versions
SE9302414L (sv
SE9302414D0 (sv
Inventor
Carl-Johan Aurell
Per Melin
Anders Nilsson
Jerzy Trojnar
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Priority to SE9302414A priority Critical patent/SE501678C2/sv
Publication of SE9302414D0 publication Critical patent/SE9302414D0/xx
Priority to CN94192763A priority patent/CN1126999A/zh
Priority to JP7504493A priority patent/JPH09502427A/ja
Priority to PCT/SE1994/000674 priority patent/WO1995002609A1/en
Priority to PL94312568A priority patent/PL312568A1/xx
Priority to CZ9698A priority patent/CZ9896A3/cs
Priority to AU72406/94A priority patent/AU676071B2/en
Priority to CA002163114A priority patent/CA2163114A1/en
Priority to HU9503768A priority patent/HUT74874A/hu
Priority to EP94921875A priority patent/EP0791012A1/en
Priority to IL11026794A priority patent/IL110267A0/xx
Priority to ZA945090A priority patent/ZA945090B/xx
Priority to TW083107195A priority patent/TW268009B/zh
Publication of SE9302414L publication Critical patent/SE9302414L/
Publication of SE501678C2 publication Critical patent/SE501678C2/sv
Priority to KR1019950705294A priority patent/KR960702848A/ko
Priority to NO955059A priority patent/NO955059D0/no
Priority to FI960119A priority patent/FI960119A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SE9302414A 1993-07-13 1993-07-13 Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid SE501678C2 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE9302414A SE501678C2 (sv) 1993-07-13 1993-07-13 Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
JP7504493A JPH09502427A (ja) 1993-07-13 1994-07-07 オキシトシン拮抗薬活性を示すペプチド
HU9503768A HUT74874A (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity and pharmaceutical compositions containing them as active component
EP94921875A EP0791012A1 (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity
PCT/SE1994/000674 WO1995002609A1 (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity
PL94312568A PL312568A1 (en) 1993-07-13 1994-07-07 Peptides having antagonistic action in relation to oxytocin
CZ9698A CZ9896A3 (en) 1993-07-13 1994-07-07 Peptide suppressing oxytocin activity
AU72406/94A AU676071B2 (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity
CA002163114A CA2163114A1 (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity
CN94192763A CN1126999A (zh) 1993-07-13 1994-07-07 具有催产素拮抗剂活性的肽类化合物
IL11026794A IL110267A0 (en) 1993-07-13 1994-07-11 Peptide exhibiting oxytocin antagonistic activity
ZA945090A ZA945090B (en) 1993-07-13 1994-07-13 Peptides exhibiting oxytocin antagonistic activity
TW083107195A TW268009B (no) 1993-07-13 1994-08-05
KR1019950705294A KR960702848A (ko) 1993-07-13 1995-11-27 옥시토신 길항적 활성을 나타내는 펩티드
NO955059A NO955059D0 (no) 1993-07-13 1995-12-13 Peptider som utviser oksytocin antagonistisk aktivitet
FI960119A FI960119A0 (fi) 1993-07-13 1996-01-10 Peptidit, joilla on oksitosiinin vastaista aktiivisuutta

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9302414A SE501678C2 (sv) 1993-07-13 1993-07-13 Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid

Publications (3)

Publication Number Publication Date
SE9302414D0 SE9302414D0 (sv) 1993-07-13
SE9302414L SE9302414L (sv) 1995-01-14
SE501678C2 true SE501678C2 (sv) 1995-04-10

Family

ID=20390606

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9302414A SE501678C2 (sv) 1993-07-13 1993-07-13 Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid

Country Status (16)

Country Link
EP (1) EP0791012A1 (no)
JP (1) JPH09502427A (no)
KR (1) KR960702848A (no)
CN (1) CN1126999A (no)
AU (1) AU676071B2 (no)
CA (1) CA2163114A1 (no)
CZ (1) CZ9896A3 (no)
FI (1) FI960119A0 (no)
HU (1) HUT74874A (no)
IL (1) IL110267A0 (no)
NO (1) NO955059D0 (no)
PL (1) PL312568A1 (no)
SE (1) SE501678C2 (no)
TW (1) TW268009B (no)
WO (1) WO1995002609A1 (no)
ZA (1) ZA945090B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
DE60309847T2 (de) 2002-02-27 2007-10-18 Ferring B.V. Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga
MX2018004282A (es) 2015-10-06 2018-08-09 Ferring Bv Nuevos procedimientos de fabricacion de barusiban y sus intermedios.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5373089A (en) * 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
SE501677C2 (sv) * 1993-06-18 1995-04-10 Ferring Bv Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel

Also Published As

Publication number Publication date
HUT74874A (en) 1997-02-28
WO1995002609A1 (en) 1995-01-26
ZA945090B (en) 1995-02-22
CN1126999A (zh) 1996-07-17
CZ9896A3 (en) 1996-06-12
CA2163114A1 (en) 1995-01-26
JPH09502427A (ja) 1997-03-11
SE9302414L (sv) 1995-01-14
SE9302414D0 (sv) 1993-07-13
EP0791012A1 (en) 1997-08-27
NO955059L (no) 1995-12-13
KR960702848A (ko) 1996-05-23
FI960119A (fi) 1996-01-10
NO955059D0 (no) 1995-12-13
AU676071B2 (en) 1997-02-27
TW268009B (no) 1996-01-11
PL312568A1 (en) 1996-04-29
IL110267A0 (en) 1994-10-21
AU7240694A (en) 1995-02-13
HU9503768D0 (en) 1996-02-28
FI960119A0 (fi) 1996-01-10

Similar Documents

Publication Publication Date Title
KR100463132B1 (ko) 헵타펩티드 옥시토신 동족체
AU2010244857A1 (en) High penetration prodrug compositions of peptides and peptide-related compounds
JP2837352B2 (ja) 胃腸運動活性を抑制するモチリン類似ポリペプチド
JP4578470B2 (ja) ソマトスタチンベクター
US5620959A (en) Bombesin antagonists
JP2949129B2 (ja) 胃腸運動刺激活性を有するモチリン類似ポリペプチド
JP2001518515A (ja) リウマチ性関節炎の治療組成物および治療方法
US6316414B1 (en) Somatostatin analogs for the treatment of cancer
SE501678C2 (sv) Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
US6316413B1 (en) Peptide agonists of bradykinin B2 receptor
WO2001062777A1 (en) Bombesin analogs for treatment of cancer
PT98498A (pt) Processo para a preparacao de polipeptidos e de composicoes farmaceuticas que os contem
EP1198478B1 (en) Somatostatin analogs and their use for the treatment of cancer
Sakura et al. Structure-activity relationships of neuromedin U. IV. Absolute requirement of the arginine residue at position 7 of dog neuromedin U-8 for contractile activity
CA2405724C (en) Substance p analogs for the treatment of cancer
IE912378A1 (en) Derivatives of pituitary posterior lobe hormones
JP3743794B2 (ja) ボンベシン類似体
CZ993A3 (en) derivatives of neurohypophysis lobe hormones

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 9302414-9

Format of ref document f/p: F